VC
Value Add VC
⚡HomePulse⚡Helpful Apps📝Blog
← Pulse/Companies

Sanofi on Pulse

Biotech

The full thread of our Sanofi coverage — a running record of every development we've tracked, with the VC take on each.

2
Stories
2
With a headline figure
Jul 10, 2026
Since

Coverage Timeline

newest first
  1. Jul 24, 2026IPOScribe Therapeutics Prices Upsized IPO With Sanofi Backing$128.7M Raised→
  2. Jul 10, 2026IPODoudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO$180M+ partnership payments→

All Coverage

IPO· Jul 24, 2026

Scribe Therapeutics Prices Upsized IPO With Sanofi Backing

Illustration for: Scribe Therapeutics Prices Upsized IPO With Sanofi Backing
IPO$128.7M Raised

Scribe Therapeutics Prices Upsized IPO With Sanofi Backing

Gene-editing biotech Scribe Therapeutics priced an upsized IPO at $15 per share, raising $128.7 million with Sanofi as a strategic anchor investor, the first gene-editing IPO in over two years.

Jul 24, 2026
IPO· Jul 10, 2026

Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO

Illustration for: Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO
IPO$180M+ partnership payments

Doudna-Founded Scribe Therapeutics Files S-1/A for Nasdaq IPO

Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.

Jul 10, 2026
@Trace_Cohen·t@nyvp.com